down arrow

CG Oncology, Inc.

  • Market Cap: N/A
  • Industry: Miscellaneous
  • ISIN: US1569441009
USD
40.08
1.05 (2.69%)

Dec 22

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

38.9640.95

52 Week

14.8046.01
Valuation
Technical
Day's Volume

CASH

569.27 k

Shareholding (Mar 2025)

FII

20.65%

Held by 68 FIIs

DII

30.68%

Held by 31 DIIs

Promoter

25.36%

How big is CG Oncology, Inc.?

22-Jun-2025

As of Jun 18, CG Oncology, Inc. has a market capitalization of $2,000.15 million, with net sales of $0.66 million and a net profit of -$105.56 million over the latest four quarters. The company reported shareholder's funds of $733.38 million and total assets of $754.80 million as of Dec 24.

Market Cap: As of Jun 18, CG Oncology, Inc. has a market capitalization of 2,000.15 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, CG Oncology, Inc. reported net sales of 0.66 million and a net profit of -105.56 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 733.38 million and total assets of 754.80 million.

Read More

What does CG Oncology, Inc. do?

22-Jun-2025

CG Oncology, Inc. is a small-cap company in the miscellaneous industry, reporting net sales of $0 million and a net loss of $34 million as of March 2025. It has a market cap of approximately $2 billion and does not pay dividends.

Overview: <BR>CG Oncology, Inc. operates in the miscellaneous industry and is classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2,000.15 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.98 <BR>Return on Equity: -12.49% <BR>Price to Book: 2.84<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is CG Oncology, Inc. overvalued or undervalued?

25-Jun-2025

As of May 13, 2025, CG Oncology, Inc. is classified as overvalued with a valuation grade of "does not qualify" due to extremely negative financial ratios and poor operational performance, including a Return on Capital Employed of -691.63% and a year-to-date return of -10.53%.

As of 13 May 2025, the valuation grade for CG Oncology, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently classified as overvalued, given its high Price to Book Value of 2.91 and extremely negative ratios such as EV to EBIT and EV to EBITDA at -11.89. Additionally, the Return on Capital Employed (ROCE) is alarmingly low at -691.63%, which raises concerns about the company's operational efficiency.<BR><BR>In comparison with peers, CG Oncology, Inc. shows a stark contrast, with its EV to EBITDA ratio of -11.4449 compared to the industry average. Notably, its performance has lagged behind the S&P 500, with a year-to-date return of -10.53% versus the index's 2.44%. Given these metrics, it is clear that CG Oncology, Inc. is not only overvalued but also struggling significantly in its operational performance.

Read More

Is CG Oncology, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, CG Oncology, Inc. has shifted to a bullish trend, supported by strong daily moving averages and weekly indicators, though caution is advised due to a bearish weekly RSI, while it has outperformed the S&P 500 significantly over the past week and month but lagged over the past year.

As of 11 September 2025, the technical trend for CG Oncology, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong indication from the daily moving averages and the weekly MACD, KST, and Bollinger Bands all showing bullish signals. However, the weekly RSI is bearish, which suggests some caution. The Dow Theory and OBV indicate a mildly bullish trend on both weekly and monthly time frames. <BR><BR>In terms of performance, CG Oncology has significantly outperformed the S&P 500 over the past week (17.07% vs. 1.05%) and month (48.56% vs. 2.33%), while trailing over the past year (4.75% vs. 17.14%).

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 2,569 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.99

stock-summary
Return on Equity

-19.11%

stock-summary
Price to Book

3.83

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-41 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.21%
0%
8.21%
6 Months
56.87%
0%
56.87%
1 Year
39.8%
0%
39.8%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

CG Oncology, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-52.10%
EBIT Growth (5y)
-292.14%
EBIT to Interest (avg)
-60.91
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.98
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.91
EV to EBIT
-11.89
EV to EBITDA
-11.89
EV to Capital Employed
82.22
EV to Sales
1196.70
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-691.63%
ROE (Latest)
-12.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 45 Schemes (23.31%)

Foreign Institutions

Held by 68 Foreign Institutions (20.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -119.05% vs -62.93% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-48.60",
          "val2": "-25.80",
          "chgp": "-88.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-41.40",
          "val2": "-18.90",
          "chgp": "-119.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-232,909.90%",
          "chgp": "23,290.99%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 450.00% vs 0.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -81.07% vs -37.29% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.10",
          "val2": "0.20",
          "chgp": "450.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-114.60",
          "val2": "-55.40",
          "chgp": "-106.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-88.00",
          "val2": "-48.60",
          "chgp": "-81.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-100,672.50%",
          "val2": "-271,808.80%",
          "chgp": "17,113.63%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-48.60
-25.80
-88.37%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-41.40
-18.90
-119.05%
Operating Profit Margin (Excl OI)
0.00%
-232,909.90%
23,290.99%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -119.05% vs -62.93% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1.10
0.20
450.00%
Operating Profit (PBDIT) excl Other Income
-114.60
-55.40
-106.86%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-88.00
-48.60
-81.07%
Operating Profit Margin (Excl OI)
-100,672.50%
-271,808.80%
17,113.63%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 450.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -81.07% vs -37.29% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About CG Oncology, Inc. stock-summary
stock-summary
CG Oncology, Inc.
Miscellaneous
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."